Anlotinib Enhances the Antitumor Activity of High‐Dose Irradiation Combined with Anti‐PD‐L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer

Abstract

Our findings indicate that anlotinib might be a potential synergistic treatment for radioimmunotherapy to achieve better antitumor efficacy in NSCLC patients by potentiating the tumor immune microenvironment.